AtCor wins $1.1m deal for SphygmoCor XCEL
15 August, 2012 by Dylan Bushell-EmblingAtCor Medical (ASX:ACG) has secured a $1.1 million contract to provide its SphygmoCor XCEL cardiac monitoring system to an international pharmaceutical company.
Bioniche to sell equine probiotic
14 August, 2012 by Dylan Bushell-EmblingBioniche (ASX:BNC) is continuing to build up its animal health product portfolio, signing a deal to allow it to distribute an equine probiotic.
AusBiotech comments on the National Research Investment Plan discussion paper
14 August, 2012 by AusBiotechAusBiotech has made a formal response to the Federal Government’s discussion paper on the National Research Investment Plan (NRIP) giving the Australian Research Committee (ARCom) a biotechnology industry perspective.
Nexvet signs first deal for veterinary drug
10 August, 2012 by Dylan Bushell-EmblingVeterinary drug developer Nexvet has signed the first licensing deal covering a biologic drug adapted for animal use using its PETization process.
Advanced Leadership Program scholarships for AusBiotech members
09 August, 2012 by AusBiotechWoman & Leadership Australia has announced two $11,000 scholarships to be awarded to AusBiotech members to assist their participation in the Advanced Leadership Program.
Bioniche E. coli vaccine cleared for import into UK
09 August, 2012 by Dylan Bushell-EmblingA UK department has granted veterinarians special dispensation to import a cattle vaccine against E. coli O157 developed by Bioniche (ASX:BNC).
GeneWorks develops DNA barcoding tech
08 August, 2012 by Dylan Bushell-EmblingSouth Australia's GeneWorks has developed a DNA barcoding security technology compatible with existing forensic laboratory instruments.
GTG gets CE Mark for breast cancer test
08 August, 2012 by Dylan Bushell-EmblingGenetic Technologies (ASX:GTG) has won European CE Mark approval for BREVAGen, its DNA test for increased breast cancer risk.
Recall costs drag down Cochlear FY12 profit
07 August, 2012 by Dylan Bushell-EmblingCochlear Limited (ASX:COH) has reported a 68% slump in FY12 profit to $56.8 million due to hefty costs associated with the voluntary recall of its Nucleus Cl500 implants.
Universal Biosensors slashes 1H loss in half
07 August, 2012 by Dylan Bushell-EmblingUniversal Biosensors (ASX:UBI) more than halved its losses for the first half of 2012, on the back of a 133% increase in revenue.
Vic Gov listens to concern on clinical trial insurance
07 August, 2012 by AusBiotechCognisant of industry concern, the Victorian Managed Insurance Authority (VMIA) has chosen not to increase the insurance requirements for commercial sponsors of human clinical trials in Victoria, which was intended to take effect from 1 July 2012.
ResMed stock bounce on record quarterly profit
06 August, 2012 by Dylan Bushell-EmblingResMed (ASX:RMD) shares up following 12% increase in FY12 profit, on the back of another quarter of record revenue and net income.
Sirtex to triple US manufacturing capacity
03 August, 2012 by Dylan Bushell-EmblingSirtex (ASX:SIR) will spend $4m over the next 18 months to expand threefold its US manufacturing capacity for SIR-Spheres doses.
Brian McNamee to step down from CSL next July
03 August, 2012 by Dylan Bushell-EmblingCSL's (ASX:CSL) CEO for the last 22 years, Dr Brian McNamee, will hand the reins to successor Paul Perrault in July 2013.
AusBiotech responds to NSW’s draft Manufacturing Industry Action Plan
02 August, 2012 by AusBiotechAusBiotech has undertaken extensive consultation with its NSW medical technology members through an open consultation forum and private meetings and responded to the draft NSW Manufacturing Industry Action Plan.
